Monday, June 10, 2013

• Stemline Therapeutics' SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)GlobeNewswire( (Mon, Jun 10)

Friday, May 31, 2013

• Stemline Therapeutics to Present at the Jefferies 2013 Global Healthcare ConferenceGlobeNewswire( (Fri, May 31)

Thursday, May 30, 2013

• Stemline Therapeutics Announces Presentations at the 2013 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire( (Thu, May 30)

Thursday, May 23, 2013

• Stemline Therapeutics Announces Exercise of Option to Purchase Additional SharesGlobeNewswire( (Thu, May 23)

Wednesday, May 22, 2013

• Stemline Therapeutics Announces Closing of $60 Million Public Offering of Common StockGlobeNewswire( (Wed, May 22)

Thursday, May 16, 2013

• Stemline Therapeutics Prices $60 Million Public Offering of Common StockGlobeNewswire( (Thu, May 16)

Thursday, April 25, 2013

• Stemline Therapeutics to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013GlobeNewswire( (Thu, Apr 25)

Monday, April 8, 2013

• Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, JapanGlobeNewswire( (Mon, Apr 8)

Monday, April 1, 2013

• Stemline Therapeutics Reports Year-End 2012 Financial ResultsGlobeNewswire( (Mon, Apr 1)